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Abstract
The survival time of HIV/AIDS patients in Korea has increased since HAART (highly active anti-retroviral therapy) was introduced.
However, the occurrence of drug-resistant strains requires new anti-retroviral drugs, one of which, an integrase inhibitor (INI), was
approved by the US Food and Drug Administration (FDA) in 2007. INIs have been used for therapy in many countries and are about to
be employed in Korea. Therefore, it is important to identify basic mutant variants prior to the introduction of INIs in order to estimate
their efﬁcacy. To monitor potential drug-resistant INI mutations in Korean HIV/AIDS patients, the polymorphism of the int gene was
investigated together with the pol gene using a genotypic assay for 75 randomly selected Korean HIV-1 patients newly diagnosed in
2007. The drug-resistant mutation sequences were analysed using the Stanford HIV DB and the International AIDS Society resistance
testing-USA panel (IAS-USA). Seventy strains of Korean subtype B were compared with foreign subtype-B strains, and there were no
signiﬁcantly different variants of the int gene region in the study population. Major mutation sites in the integrase (E92Q, F121Y,
G140A/S, Y143C/R, Q148H/R/K and N155H) were not detected, and only a few minor mutation sites (L74M, V151I, E157Q, V165I,
I203M, S230N and D232N) were identiﬁed in 21 strains (28%). Resistance due to mutations in the pol gene was observed in a single
strain (1.3%) resistant to protease inhibitors (PIs) and in four strains (5.3%) resistant to reverse transcriptase inhibitors (RTIs). In
summary, this demonstrates that INIs will be susceptible to drug naı¨ve HIV/AIDS patients in Korea.
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Introduction
The ﬁrst AIDS (acquired immune deﬁciency syndrome)
patient was identiﬁed in 1981, and HIV was found to be the
cause of AIDS in 1983 [1]. Currently, 33.2 million people are
living with HIV, and deaths caused by AIDS reached 2.1 mil-
lion in 2007 according to a report from the Joint United
Nations Programme on HIV/AIDS (UNAIDS) [2]. The inten-
sive use of anti-retroviral drugs has reduced the mortality
and morbidity of HIV/AIDS patients. These drugs suppress
viral replication and reduce the level of HIV RNA loads in
patients’ plasma, helping to maintain the patient’s immune
system and resulting in mortality reduction. The use of PIs
(protease inhibitors) resulted in a sharp decrease in morbid-
ity in 1996 [3]. Six classes and 25 kinds of anti-retroviral
drugs have been approved by the FDA (Food and Drug
Administration) and are used for clinical purposes.
Since the worldwide introduction of combination therapy
(highly active antiretroviral therapy, HAART) with PIs, nucle-
oside/nucleotide reverse transcriptase inhibitors (NRTIs) and
non-nucleoside reverse transcriptase inhibitors (NNRTIs),
many drug-resistant variants of the virus have appeared [4].
These drug-resistant strains are known to be transmitted to
drug-naı¨ve HIV/AIDS patients [5]. Thus, development of new
drugs targeting new domains of the virus is necessary in
order to increase treatment efﬁciency. The integrase (int)
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gene, which encodes a peptide of 288 amino acids organized
into three domains and located at the 3¢ end of the pol gene,
is a new target for anti-retroviral drugs [6]. The integrase
gene directs a two-step process involving 3¢-OH processing
to remove dinucleotides from the 3¢ end of each long termi-
nal repeat (LTR) and strand transfer to integrate the viral
DNA into the host DNA [7].
Raltegravir, the ﬁrst INI approved by the FDA (2007), is
highly effective but resistance does occur with virological
failure. However, pre-existing resistance is exceedingly rare.
It has been commercialized in the USA and Europe and is
increasingly used to treat HIV/AIDS patients [8,9]. The major
INI mutations occur primarily in the CTD (C-terminal
domain). The sites have been characterized as E92Q, F121Y,
G140A/S, Y143R/C, Q148H/R/K and N155H by the Stanford
DB algorithm, and Y143R/H/C, Q148H/R/K and N155H by
the International AIDS Society resistance testing-USA panel
(IAS-USA panel) algorithm [10,11]. The prevalence of INI
(Raltegravir)-resistant viral strains has not yet been reported,
although some studies have found that 95% of Raltegravir-
treated patients were susceptible to the drug and showed
decreases in viral load to fewer than 50 copies/mL [12].
Statistical analysis of the prevalence of resistance to PIs,
NRTIs and NNRTIs in Korea demonstrated that HAART-
treated patients showed increased resistance to NNRTIs.
However, there was no noticeable change in the prevalence
of drug resistance in drug-naı¨ve patients from 1999 to 2005
[13]. Currently, there are plans to commercialize INI in
Korea. Therefore, it is necessary to characterize the INI-
resistant sequences and to analyse the variants present in
the Korean population. In 2007, the viral gene sequences
from newly diagnosed HIV-anti-retroviral drug-naı¨ve Korean
patients were compared and the polymorphisms of the vari-
ants were analysed for INI resistance.
Material and Methods
Study populations and RNA extraction
To investigate anti-retroviral drug-resistant variants, plasma
samples from 75 individuals who had not been treated with
HAART were collected for genotypic assay of the int gene
region. These patients were randomly chosen from 744 HIV-
1 Korean patients who were newly diagnosed in 2007.. Of
the seventy-ﬁve individuals chosen, 70 were subtype B and
ﬁve were non-B. HIV-1 RNA was extracted directly from
the plasma by silica binding using a NucliSens Extraction kit
(bioMe´rieux, Boxtel, the Netherlands) and used for geno-
typic assays after quantitation with a NucliSens EasyQ HIV-
1 v1.1 (bioMe´rieux) based on the NASBA (nucleic acid
sequence-based ampliﬁcation) method. Patient information
was made anonymous before analysis and converted to des-
ignated labels at the Korea Center for Disease Control and
Prevention (KCDC).
RT-PCR and sequencing of the HIV int gene together with
pol gene
The HIV pol gene was ampliﬁed by reverse transcription-
polymerase chain reaction (RT-PCR) using PCR conditions
based on the integrase genotypic assay, a laboratory protocol
for sequencing the int gene together with the other regions
of pol. Following RT–PCR, a nested PCR reaction was per-
formed with the primer set P2 (HXB2 2042-2062, 10 pmol/
lL, forward) and P16 (HXB2 5186-5166, 10 pmol/lL,
reverse). A Millipore PCR Cleanup kit (Promega, Madison,
WI, USA) was used to purify the PCR products [14].
The PCR pol product (about 3.14 kb) containing the entire
PR and RT with the IN gene sequence was subjected to
direct sequencing using the ABI Prism Dye Terminator Cycle
Sequencing Ready Reaction kit (PerkinElmer, Waltham, MA,
USA) in an automated sequencer (ABI Prism 3110 DNA
Sequencer; Applied Biosystems, Foster City, CA, USA) [15–
17].
All sequences of the 75 patients’ strains were submitted
to GenBank (GenBank accession number HM051417–
HM051491).
Genotypic resistance assays and phylogenetic analysis
Subtyping was conducted using 29 reference strains from the
Los Alamos HIV DB. Five hundred and sixty-nine strains
from other countries (206 strains from Austrailia, 159 strains
from the USA, 131 strains from Spain, 58 strains from Ger-
many and 15 strains from Belgium) were used for the analy-
sis [14,18]. The pol nucleotide and amino acid sequences
were aligned using the EDITSEQ and MEGALIGN programs in the
Lasergene software package (DNASTAR Inc., Madison, WI,
USA). Sequence alignments were further processed using
PAUP* (version 4.0b10; Sinauer Associates, Inc., Sunderland,
MA, USA) [19]. Resistance rates and patterns of drug-resis-
tant mutations were analysed using the Stanford HIV DB as
well as the International AIDS Society resistance testing-USA
panel (IAS-USA).
Results
Demographic characteristics of the study population and
phylogenetic analysis of the HIV-1 pol gene
The demographic characteristics of 75 patients were analy-
sed; these patients were chosen from the HIV-1 patients
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newly infected in 2007. The median age was 40 years, with a
range between 19 and 73; 53 (70.7%) out of the 75 patients
were between the ages of 20 and 49 years old, and 22
(29.3%) patients were 50 or above (data not shown). Sev-
enty-three of the 75 patients (97.3%) were male and two
patients (2.7%) were female. With regard to transmission
routes, 43 patients (57.3%) were heterosexual and 14
patients (18.7%) were homosexual. The mean plasma HIV
RNA level was 5.52 log copies/mL and the mean CD4+ T-
cell count was 252 cells/mm3 (Table 1).
A phylogenetic tree analysis (Fig. 1) demonstrated that
most of the sequences in the study population belonged to
HIV-1 subtype B (n = 70, 93.3%). The remainder were iden-
tiﬁed as non-B (6.7%) containing CRF01_AE (n = 4) and
CRF02_AG (n = 1).
Drug-resistance-related mutations in Korean HIV-1 subtype B
Seventy strains of subtype B from 75 Korean HIV-1 isolates
and 569 stains from foreign HIV-1 isolates were compared
using the Stanford HIV DB algorithm as well as the Interna-
tional AIDS Society resistance testing-USA panel (IAS-USA)
in order to analyse the integrase mutations conferring resis-
tance against INIs (Table 2).
No signiﬁcant mutation sites conferring resistance to INIs
were detected in the Korean strains. Minor mutation sites
were found in 21 Korean strains (28%) and major mutation
sites were detected in other countries only (Table 2).
Table 3 shows the prevalence of anti-retroviral drug resis-
tance for INI, RTI and PI with the comparison between 2007
and 1999–2005 [13]. Resistance was not detected against
INIs during 2007 in Korea, and there was a lower prevalence
of resistance against other anti-retroviral drugs, including PIs,
NRTIs and NNRTIs. Four (5.3%) of the 75 strains showed
resistance during 2007, one strain (1.3%) demonstrated resis-
tance against PIs, three strains (4%) showed resistance
against NRTIs, and two strains showed resistance (2.7%)
against NNRTIs.
TABLE 1. Demographic characteristics of the Korean study
population of HIV-infected drug-naı¨ve patients
Characteristics
Drug-naı¨ve patients
n = 75 (%)
Gender, n (%)
Male 73 (97.3)
Female 2 (2.7)
Age (year)
Median 40
Range 19–73
Transmission route
Homosexual contact 14 (18.7)
Heterosexual contact 43 (57.3)
Unidentiﬁed 18 (24.0)
Plasma HIV RNA level
Mean log copies/mL 5.52
Range 3.08–6.48
CD4 T-cell count
Mean CD4+ T-cell/mm3 (n = 33a) 252
n, number of cases.
aNo. of tested cases (33 means the number of available cases for CD4 T + cell
count testing results, out of 75 individuals’ results, which were checked within
3 months from the checkpoint of the drug resistance test).
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FIG. 1. Phylogenetic tree analysis of the HIV-1 pol gene from drug-
naı¨ve patients (n = 75) and 29 reference sequences. The tree was con-
structed by the neighbour-joining method using the PAUP program. The
length of each of the horizontal bars relative to each other is propor-
tional to the divergence between the sequences. Numbers at the
nodes represent the bootstrap values for those nodes from 1000 boot-
strap re-samplings. The reference strain is represented as a number at
the end of each branch (1:ANT70_N, 2:YBF30_N, 3:92BR025_C,
4:ETH2220_C, 5:92NG083_G, 6:SE6165_G, 7:IBNG_CRF02_AG,
8:92UG037_A1, 9:U455_A1, 10:CM240_CRF01_AE, 11:93BR020_F1,
12:MP255_F2, 13:EQTB11_K, 14:MP535_K, 15:94UG114_D, 16:NDK_D,
17:WEAU160_B, 18:MN_B, 19:JRFL_B, 20:HXB2_B, 21:LAI_B,
22:NY5CG_B, 23:PNL43_B, 24:RF_B, 25:OYI_B, 26:SF2CG_B,
27:SE9173_J, 28:SE92809_J, 29:90CR056_H).
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Discussion
Since Zidovudine (AZT) was ﬁrst introduced in Korea in 1991,
different types of anti-retroviral drugs have been introduced
[13]. The drugs suppress viral replication and repress HIV RNA
loads to low levels in plasma. However, resistant virus strains
result in the failure of drug treatment and induce serious prob-
lems upon transmission to drug-naı¨ve hosts as well, causing
reduced therapeutic efﬁcacy for HAART. Thus, anti-retroviral-
resistant strains have been monitored on a worldwide scale
using genotypic assays, and these assays are recommended for
drug-naı¨ve HIV/AIDS patients [5]. In Korea, surveillance for
anti-retroviral drug resistance has been conducted since 1999.
In general, its prevalence has been low and similar each year.
However, resistance against the RTIs has been increasing since
2000, and resistance to other drugs increased slightly, from
4.3% (1999–2005) to 5.3% (2007). Thus, the continuous study
of drug resistance is critical (Table 3).
In this study, new analytical conditions for the int gene
were optimized to extend genotype testing sites to the
entire pol gene, so that the pol and int regions can be moni-
tored at once. Integrase polymorphisms were investigated
using these conditions to examine sites related to various
drug resistances. Emphasis was placed on monitoring poten-
tial mutations that could result in INI resistance in HIV-1-
infected drug-naı¨ve Korean patients identiﬁed in 2007 prior
to INI introduction.
This study population showed no major mutation sites
that would cause resistance to INI among the subtype-B
strains isolated from 70 patients. Only seven minor mutation
sites were observed in 21 of the Korean strains and this was
little different to other countries, which showed four major
mutation sites (Table 2). Additionally, D10E, V72I, G123S,
R127K and N232D were observed as polymorphic sites at
high frequency in both Korea and other countries (data not
shown). Interestingly, V31I/M, which is not known to affect
resistance, was observed in the Korean strains with high fre-
quency compared with other countries, so it may be the
most prevalent and unique polymorphic site in Korea (data
not shown, [17,18]), and A124N was dominant in Korean
strains as well. However, A124T was observed frequently in
strains from other countries. The prevalence of major/minor
mutations in non-B viral strains was reviewed using data
available on non-B isolates from other countries in order to
analyse the differences between B and non-B subtypes. V72I
was observed as a polymorphic site in all subtypes at a high
frequency, suggesting that V72I is a frequently polymorphic
site in both subtype B and non-B. T125A was detected in
both subtypes A and C (data not shown, [19,20]).
Regarding polymorphic mutation sites, major sites of
mutation are thought to reduce viral replication and enzyme
activity, but minor mutation sites are believed to affect major
mutation sites through enzymatic changes or by compensa-
tion for defective viral function as a result of resistance
mutations that increase viral ﬁtness [21]. Nakahara et al. [22]
found that IN efﬁciency was higher with a combination of
the major/minor mutation sites Q148K/E138K and Q148/
G140S compared with the corresponding single-site mutants,
implying a crossover effect of each mutation. Sebastiaan et al.
[23] found previous drug treatment was related to IN diver-
gence, suggesting that other genetic regions may be associ-
ated with int polymorphism. Therefore, we investigated PI
and RT mutation sites using int sequence analysed samples
(Table 3). This showed the same pattern as the surveillance
result from 1999 to 2005 [13], and L101/V, V77I and I93L of
TABLE 2. Comparison of HIV-1 INI resistance mutation
sites in drug-naı¨ve Korean patients and patients from other
countries as assessed by the IAS-USA panel and the Stan-
ford DB
INI-resistance
related mutations
Korea (n = 70) Other countries
(n = 569)
No. cases (%) No. cases (%)
L74M 1 (1.4) 8 (1.4)
E92Q 0 (0.0) 0 (0.0)
F121Y 0 (0.0) 0 (0.0)
E138A/K 0 (0.0) 1 (0.2)
G140A/S 0 (0.0) 5 (0.9)
Y143C/H/R 0 (0.0) 3 (0.5)
S147G 0 (0.0) 1 (0.2)
Q148H/R/K 0 (0.0) 3 (0.5)
V151I 7 (10.0) 16 (2.8)
N155H/S 0 (0.0) 5 (0.9)
E157Q 5 (7.1) 4 (0.7)
V165I 1 (1.4) 14 (2.5)
I203M 6 (8.6) 50 (8.8)
S230N 12 (17.1) 53 (9.3)
D232N 1 (1.4) 12 (2.1)
n, number of cases.
1) Stanford DB: E92Q, F121Y, G140A/S, Y143C/R, Q148H/R/K, N155H (major
mutations, in bold), L74M, E138A/K, S147G, V151I, E157Q, V165I, I203M,
S230N, D232DN (minor mutations). 2) IAS-USA panel: Y143C/H/R, Q148H/R/
K, N155H/S (major mutations, in bold).
TABLE 3. Prevalence (%) of anti-retroviral drug resistance
based on the ‘SIR’ interpretation of the Stanford DB
Drug class
2007 (n = 75)
1999–2005
(n = 300) Choi [13]
No. cases (%) No. cases (%)
Protease inhibitor 1 (1.3) 1 (0.3)
Nucleoside/nucleotide reverse
transcriptase inhibitor
3 (4.0) 8 (2.7)
Non-nucleoside reverse
transcriptase inhibitor
2 (2.7) 4 (1.3)
Integrase inhibitor 0 (0.0)
Total 4 (5.3) 13 (4.3)
n, number of cases.
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the PI region showed high mutation frequency (data not
shown). It was impossible to ﬁnd the association between IN
polymorphism and PI/RT mutation sites; this may be due to
limited samples, which were only HAART naı¨ve samples.
Thus, the effect of not only the mutation sites against
different kinds of drug, but also the range of major/minor
mutation sites against each drug should be more investigated
by using HAART experienced samples, including the effect of
PI mutation sites on INI mutation sites in terms of viral repli-
cation capacity or drug resistance. It would have been helpful
if intravenous drug user cases were also analysed in this
study because it is known that intravenous drug use is a risk
factor for HIV transmission. However, there are almost no
intravenous drug users among HIV-1-infected patients in
Korea; only two cases of intravenous drug use out of 5634
patients were found to be registered as of December 2009
in Korea; thus it was hard to investigate intravenous drug
users due to a lack of cases.
In summary, because only minor mutation sites were
detected in Korean HIV-1 strains, it may not be necessary to
perform INI resistance tests for HIV-1 INI drug-naı¨ve Korean
patients. However, the surveillance of INI resistance should
be carried out at a population level in order to monitor
potential mutation sites for INI drug resistance. In particular,
potential mutations’ effects on INI therapy need to be fur-
ther elucidated using genotypic assays in combination with
phenotypic assays as well.
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